A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 29, 2016

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2019

Conditions
Scleroderma
Interventions
DRUG

BMS-986020

OTHER

Placebo

Trial Locations (27)

10021

Local Institution, New York

10032

Local Institution, New York

12206

Local Institution, Albany

15219

Local Institution, Pittsburgh

20037

Local Institution, Washington D.C.

20057

Local Institution, Washington D.C.

21205

Local Institution, Baltimore

29425

Local Institution, Charleston

44195

Local Institution, Cleveland

48109

Local Institution, Ann Arbor

60611

Local Institution, Chicago

77030

Local Institution, Houston

80045

Local Institution, Aurora

85259

Local Institution, Scottsdale

90095

Local Institution, Los Angeles

94305

Local Institution, Stanford

02114

Local Institution, Boston

02118

Local Institution, Boston

08903

Local Institution, New Brunswick

L8N 1Y2

Local Institution, Hamilton

N6A 4L6

Local Institution, London

85-681

Local Institution, Bydgoszcz

20-954

Local Institution, Lublin

60-218

Local Institution, Poznan

71-252

Local Institution, Szczecin

02-507

Local Institution, Warsaw

NW3 2QG

Local Institution, London

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY